
Oscar Health looks like a screaming buy — growing revenue, growing members, positive free cash flow. So why does the market keep discounting it? We ran the numbers.Oscar Health (OSCR) just posted strong headline numbers: member growth accelerating past 3 million, revenue climbing, free cash flow positive. Health insurers don't get valued like typical growth stocks — and free cash flow is one of the most misleading metrics you can use here.In this episode, we break down why insurance float — not free cash flow — is the real driver of Oscar's balance sheet, how the medical loss ratio (MLR) caps profitability by regulation, and why receivables and payables to CMS matter more than most investors realize. We also walk through two reverse DCF scenarios on GAAP earnings per share — a 10-year model and a more aggressive 3-year model — to see what growth rate the market is actually pricing into OSCR today.Think of it as a masterclass in valuing any financials-driven business — insurance, banks, specialty finance — differently than you'd value a software or semiconductor company. We also give a first look at the new investment thesis checklist tool and segment/KPI dashboard inside Semiconductor Insider.TIMESTAMPS0:00 - Why Oscar Health Looks Cheap (And Why That's Misleading)1:04 - Revenue, Member Growth & Free Cash Flow Overview2:00 - The Problem: Free Cash Flow Isn't Real Cash Flow Here2:40 - Medical Loss Ratio Explained: The 80% Rule3:03 - Insurance Float 101 (The Berkshire Hathaway Playbook)4:38 - Reading the Balance Sheet: Premiums, Payouts & SG&A5:24 - CMS Receivables & Payables: The Hidden ACA Liability7:00 - Reverse DCF: 10-Year vs. 3-Year Growth Scenarios9:07 - Building a Custom Investment Thesis Checklist10:40 - Final Takeaway: How to Actually Value Oscar Health—If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.comAll our socials: https://linktr.ee/chipstockinvestorIf you're getting value from the show, follow so you don't miss the next one.—Disclosure: Some links above are affiliate links. If you buy something through them, we might earn a little coffee money — thanks for helping us (Kasey) fuel our caffeine addiction.Content in this episode is for general information or entertainment only and is not specific or individual investment advice. Forecasts and information presented may not develop as predicted, and there is no guarantee any strategies presented will be successful. All investing involves risk, and you could lose some or all of your principal. CSI doesn't own shares of Oscar Health.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Twist Bioscience Soared — We're Still Not Buying

The Fastest-Growing Chip Stock Is Also the Most Hated

AI Data Center Spending Means Good Times For Semiconductors Continue -- Oracle ORCL Stock Analysis

Nvidia's Biggest Acquisition Ever: $12.9B for Hugging Face (Can It Survive Regulators?)
Free AI-powered recaps of Chip Stock Investor Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.